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ABSTRACT 
THE EFFECT OF ARGININE VASOTOCIN ON CRYOPROTECTANT 
 PRODUCTION DURING FREEZING IN  
THE PACIFIC CHORUS FROG,  
Pseudacris regilla 
by  
Ben Ingels 
February 2017 
 Freeze Tolerance is an adaptation seen amongst several species of amphibians as 
a way of surviving during wintering months. Use of cryoprotectants is seen in all freeze 
tolerant species (glucose/glycerol). Synthesis and transportation mechanisms that regulate 
this process are not yet fully understood. Arginine vasotocin is a neurohypophyseal 
peptide known to have glycogenolytic effects as well as regulate several key processes 
involved in fluid and solute transportation. Although one prior study suggested that AVT 
is not involved in responses to freezing, I measured AVT levels during freezing and 
injected an AVT antagonist to see if it would affect the production of cryoprotectants 
within liver and thigh muscle during freezing. There was a dramatic increase in systemic 
AVT levels (p=0.05) during freezing by Pseudacris regilla. The AVT antagonist caused a 
dramatic reduction (~50%) in hepatic glucose and glycerol concentrations. These results 
demonstrate that AVT is involved with the process of cryoprotectant sourcing during 
freezing events in Pseudacris regilla. 
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CHAPTER I 
 
INTRODUCTION 
 Winter in the inland Pacific Northwest exposes animals to harsh, cold conditions, 
including subzero temperatures for extended periods of time. Life has developed many 
strategies to adapt to such conditions. For warm-blooded or endothermic animals, the 
choices are numerous. Some indigenous species, such as shorebirds and caribou, choose 
to simply migrate to more favorable environments. Others, such as silver-haired bats and 
hummingbirds (Carpenter and Hixon, 1988; Falxa, 2007), have developed physiological 
adaptations that allow them to temporarily lower their metabolic rate and core 
temperature to avoid excessive heat loss and conserve energy, a process known as torpor. 
Hibernation is a strategy able to extend this decrease in metabolic activity/body 
temperature for extended periods of time (Marchand, 2013). 
 For ectotherms, which are dependent on environmental heat, the choices are more 
limited. Exposure to cold, and the near unavoidable contact with ice, brings a series of 
challenges for survival. Ice formation is detrimental to life in many ways: it can cause 
physical damage to the cell by intruding through cellular structures, can cause cellular 
dehydration by loss of fluids to the growing ice crystals and denature proteins (Muldrew 
and McGann, 1988).  Other osmoregulatory processes can be adversely affected by ice 
formation. For example, dissolved solutes are excluded from growing ice crystals which 
may result in harmful accumulations within the unfrozen fluids (Muldrew and McGann, 
1988).  
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Certain amphibians living within these northern regions have developed a novel 
adaptation of tolerating the freezing of body fluids within the organism to survive 
(Schmid, 1982), an adaptation referred to as freeze tolerance. Currently, freeze tolerance 
has been observed in 12 amphibian species. These include the Gray Treefrog (Hyla 
versicolor and H. chrysoscelis), the Wood Frog (Rana sylvatica) and the Pacific Chorus 
Frog (Pseudacris regilla) (Schmid, 1982; Croes and Thomas, 2000; Costanzo et al., 
2013). The Siberian Salamander Salamandrella keyserlingii, and the Schrenck newt 
Salamandrella schrenckii, have also been documented as having this unique adaptation 
(Berman et al., 2009).  During freezing, cardiac, respiratory and brain activity cease or 
severely decrease (Storey and Storey, 1988; Costanzo et al., 1995). These functions 
reanimate upon thawing, with full function returning in one to four days (Costanzo et al., 
1995; Irwin et al., 2002). 
 Understanding the mechanisms behind freeze tolerance reveals the use of specific 
low-density molecules (glucose, glycerol, urea) as cryoprotectants to preserve cell/organ 
integrity, limit absolute dehydration and control ice formation within the organism 
(Costanzo et al., 1992; Storey and Storey, 1992, 1996). The ability to endure massive 
organ/tissue dehydration is also observed in these freeze-tolerant amphibians. During 
freezing, organs may lose up to 60% of their fluid content, largely due to the formation of 
ice crystals (Lee et al., 1992). As the cells dehydrate, intracellular solute concentrations 
increase dramatically, resulting in an effective decrease in freezing temperature, reducing 
and controlling ice formation (Lee et al., 1992). 
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Cryoprotectants 
The use of cryoprotectants to aid in the survival of freezing has been observed in 
all freeze-tolerant amphibians. Amphibians demonstrating freeze tolerance use glucose 
and glycerol as the main substrates for cryoprotection (Storey and Storey, 1996). Ice 
formation initiates a sudden and rapid increase in the synthesis of these cryoprotectants, 
which are assumed to be primarily sourced from liver glycogen (Storey and Storey, 
1996). Muscle glycogen is generally preserved for localized metabolic needs and lacks 
the necessary enzymes to convert their stores into free glucose for systemic use (Van 
Shaftingen, 2002). These liver glycogen stores are built up prior to the wintering period 
(Storey and Storey, 1996). Once inoculated with ice through skin contact, the liver begins 
a rapid breakdown of glycogen to build up cryoprotectant levels and disperse them to the 
tissues through the bloodstream (Costanzo et al., 1992).  
Cryoprotectants aid in protecting and stabilizing cell membranes from ice 
damage, and aid in the osmotic regulation required during freezing (Amaral et al., 2015). 
As cells begin to lose their fluids to ice in extracellular spaces, the concentration of 
cryoprotectants in and around the cell increases. This change creates an osmotic gradient 
that prevents complete dehydration and allows ice formation to occur at a pace slow 
enough for cellular stability and regulation to occur (Costanzo and Lee, 1994; Croes and 
Thomas, 2000; Healas, 2014). Ice sheets begin to form around tissues and within the 
abdominal/lymphatic cavities where up to 70% of the total body water can be locked up 
in ice crystals (Layne and Lee, 1987). The sequestration of ice in the lymphatic spaces 
helps to limit the amount of ice forming in other areas where physical damage to organs 
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and tissue could occur (Lee and Costanzo, 1998). Urea may also play a protective role in 
amphibians by guarding the osmotic concentration, stabilizing cell membranes, cell 
structures and macromolecules (Storey and Storey, 2004; Costanzo and Lee, 2008). 
Amphibians accumulate urea under times of inadequate environmental water as a means 
of combating dehydration (Jørgenson, 1997). Dehydration due to ice accumulation should 
therefore trigger a very similar osmotic stress response. In experiments with the wood 
frog Rana sylvatica, frogs exposed to high levels of urea saw a dramatic increase in both 
cell/tissue survivability in vitro as well as increased recovery time of neuromuscular 
functions (Costanzo and Lee, 2008). More research is needed to understand the extent of 
urea accumulation during freezing, variations between freeze-tolerant species and to what 
degree of protection urea offers during freezing. 
 
Pacific Chorus Frog; Pseudacris regilla  
The Pacific Chorus Frog, Pseudacris regilla (formerly Hyla regilla), is a species 
that has a range that extends from central British Columbia to Baja California. These 
frogs are found as far east as Montana and Nevada and all along the West Coast 
(Duellman and Sweet, 1999; Stebbins, 2003). It was first reported as freeze tolerant in 
2000 (Croes and Thomas, 2000). P. regilla has been observed overwintering beneath leaf 
litter, where it is exposed to weather conditions (Irwin, unpub. data).  Limited studies 
have examined the freezing ability of P. regilla across its range, but it has been observed 
that Washington State sea-level populations share the same level of tolerance as higher 
elevation populations (Healas, 2014). Glucose and glycerol concentrations seem to vary 
 5 
 
amongst populations of P. regilla, which could be linked to local adaptations, but more 
research is needed in this area (Healas, 2014).  
 
Glycogen, Glucose, Glycerol: Sources of Cryoprotectants 
 There are several biochemical pathways by which cryoprotectants may be 
produced (Fig 1.1). The first step of glucose production is glycolysis: the break-down of 
glycogen to free D-glucose (10% net) and a large amount of glucose-1-phosphate (90% 
net) (Gerin and Van Shaftingen, 2002). The enzyme involved in this process is glycogen 
phosphorylase, which acts to break the α1-4 glycosidic bond of the glycogen chain via 
phosphorylation, giving an end-product of glucose-1 phosphate. Glycogen debranching 
enzyme then acts as a transferase on the α1-4 glycosidic bond, as well as influencing 
glucosidase activity on the α1-6 glycosidic bonds via hydrolysis, leaving an end-product 
of unbound D-glucose. The third enzyme involved in glycogenolysis is 
phosphoglucomutase, which converts glucose-1-phosphate to the more widely used 
glucose-6-phosphate. Within the liver, glucose-6-phosphate interacts with glucose-6-
phosphatase (G6Pase) to produce free D-glucose. G6Pase is unique, being a membrane-
bound enzyme found within liver and kidney endoplasmic reticulum (Gerin and Van 
Shaftingen, 2002). 
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The initiation of freezing (via inoculation by ice) has been shown to increase the 
concentration of glucose in both the blood and liver of amphibians (Storey and Storey, 
1996). Within four minutes of the detection of ice formation, liver and blood glucose 
levels rose to 3-6fold within the species Rana sylvatica. This study concluded that the 
stimulation of glucose release is a result of extracellular signaling mediated by β-
Figure 1.1 Glycogenolysis overview: Debranching enzyme’s hydrolytic α1-6 glucosidase activity 
creates free D-glucose (10% net). Glucose-6-phosphotase is unique and found strictly in the liver to 
convert G6P into free glucose. Muscle glycogen is strictly used for localized metabolic demands, 
where G1P is free to enter Krebs cycle for ATP synthesis 
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adrenergic receptors within the plasma membrane of hepatocytes (Storey and Storey, 
1996).  Glycogen phosphorylase activity is stimulated by hormones such as epinephrine 
and glucagon, both of which increase cAMP levels and trigger cAMP-dependent protein 
kinase, PKA (Dieni et al., 2011). The β-adrenergic-blocker propranolol prevents the 
release of glucose in frozen frogs, whereas the α-adrenergic blocker phentolamine had no 
effect on glycogenolytic activity or glucose output (Storey and Storey, 1996). This 
finding is more evidence the mechanism of release of glucose is mediated via β-
adrenergic reception (Storey and Storey, 1996; Dieni et al., 2011), linked to a cAMP 
intracellular messenger system.   
 
 Aquaporins 
Aquaporins (AQPs) are a family of proteins that form selective water channels 
within the plasma membranes of various cells within the organism (Ogushi et al., 2010). 
A subgroup of AQPs act to help facilitate the transportation of small solutes such as 
glycerol and urea through selective pores. This family is known as glyceroporins or 
aquaglyceroporins (GLPs) (Zimmerman et al., 2006; Ogushi et al., 2010). The discovery 
of AQPs was in the 1990s (Agre et al., 1993); although they were previously speculated 
to exist (Brown et al., 1980; De Sousa and Grosso, 1982). AQPs have been observed 
across a myriad of taxa; ranging from bacteria to vertebrates (Suzuki et al., 2007).  
Within amphibians, specifically, 20 AQPs cDNAs have been identified and exist 
in six clusters with two being unique to the amphibians (Suzuki et al., 2007). Amphibian 
AQPs are expressed in the epithelium of the vasculature along the pelvic patch skin, 
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urinary bladder, and within the kidney (Tanii et al., 2002; Hasegawa et al., 2003; Ogushi 
et al., 2010). Epinephrine and AVT have been shown to regulate several families of 
AQPs/GLPs within amphibians (Ogushi et al., 2007; Ratycz, 2014). 
 
Arginine Vasotocin (AVT) 
Arginine vasotocin (AVT), one of two peptides released by the neurohypophysis 
in amphibians (Boyd, 2006), is homologous to arginine vasopressin in mammals. AVT 
has a variety of effects in amphibians, including osmoregulation, behavior/reproduction, 
and cardiovascular regulations. The osmoregulatory actions of AVT are on several key 
organs including the kidney, bladder and skin. AVT acts on the skin by increasing the 
water permeability by regulating expression of aquaporins within the epithelium, 
specifically in the ventral pelvic area (Hasegawa, 2003). Within the kidney, AVT causes 
vasoconstriction of preglomerular arteries which reduces glomerular filtration rates by as 
much as 85% (Boyd, 2006). In the bladder, AVT acts to stimulate movement of water 
from the bladder back into the plasma and is accompanied by the increased expression of 
aquaporins (Jo and Harris, 1995). AVT has also been observed to increase levels of cAMP 
through impacted tissues (Janssens et al., 1985; Jo and Harris, 1995). 
There are three main receptor subtypes identified for AVT in the amphibian 
(Boyd, 2012).  The VT1aR is specific for AVT and closely mirrors the V1a Vasopressin 
receptor found in mammals. The VT1bR differs from its VT1aR counterpart in its 
exclusive expression in the brain and pituitary gland. This subtype closely resembles the 
V1b Vasopressin receptor in mammals. Both of these subtypes have been shown to 
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couple with the protein kinase-C mediated signaling pathway (Boyd, 2012). The other 
vasotocin receptor type, VT2R, has a high affinity for AVT (Boyd, 2006) and is most 
similar to the V2 Vasopressin receptor in mammals. Unlike the VT1 receptors, VT2R 
uses a cAMP signaling pathway (Boyd, 2012). Hydrins are believed to be variants of pro-
AVT processing and play key roles in fluid absorption/reabsorption in the skin and 
bladder (Michel et al., 1993).  
AVT has also been shown to stimulate glycogenolysis within the liver and 
increases the activity of glycogen phosphorylase α activity and cAMP (Ade, et al.,1995; 
Boyd, 2006). AVT stimulates glycogenolysis via VT2R receptor activation (Janssens et 
al., 1986).  Research has also shown insulin can inhibit this AVT-induced glycogenolysis 
through reduction of cAMP levels within axolotl livers (Janssens and Grigg, 1992). 
Preliminary research has also shown the AVT V1a/V2 receptor antagonist, β-Mercapto-β, 
βcyclopenta-methylenepropionyl1-, O-ET-Tyr2, (Val, Arg8)) Vasopressin, reduced liver 
glucose levels in frozen Pacific Chorus Frogs (Pense, 2011). 
 To date, there has been a lack of research in understanding AVT’s role in 
cryoprotectant release and regulation during freezing in freeze-tolerant amphibians. In 
this study, I first wanted to verify Croes and Thomas’s findings that P. regilla was a 
freeze-tolerant species utilizing glucose and glycerol as cryoprotectants. I also wanted 
confirm my suspicions that AVT plays a role in the freeze-tolerance by seeing if there was 
an elevation in systemic AVT during freezing. I then wanted to see how cryoprotectant 
accumulation would be affect if the effect of AVT was inhibited during freezing. 
Measuring systemic levels of AVT during freezing would be a first, and provide an 
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evidence base for the theory AVT is involved during freezing. By measuring glucose and 
glycerol concentrations from hepatic and muscular tissues during freezing in both a 
control group and an AVT inhibited group, I would gain powerful insight into how AVT 
impacts cryoprotectant accumulation during freezing. I suspected to see elevations of 
AVT during freezing. I also expected suppressing AVT within freezing frogs would 
suppress accumulations of cryoprotectants as well.  
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CHAPTER II 
MATERIALS/METHODS 
Specimen Collection/Storage 
I collected frogs from two sites: Stampede Pass, Washington (GPS: 47°18'36.4"N 
121°18'13.6"W) and Table Mountain, Washington (GPS: 47º 14’ 36.4” N 120º 
33’33.4”W). Frogs were collected during August-September by hand and net. I held frogs 
in a secured vinyl-outdoor enclosure (8x12x24ft), with small mesh sub-enclosures 
(3x3x3ft). The enclosures were located at Engelhorn pond on the campus of Central 
Washington University. Frogs were fed ad libitum on mineral powder-dusted crickets 
twice weekly. Dead or ill frogs were immediately removed from the enclosures. On 
December 5th (before weather was cold enough to induce freezing), I relocated frogs into 
plastic box enclosures containing substrate and leaf litter sourced from the outdoor 
enclosure area. Enclosures were stored in a climate-controlled 4°C storage room. Once 
indoors, frogs began a fasting period and remained in these conditions until experiments 
began in February or March. All procedures were performed and done with approval by 
the CWU Institutional Animal Care and Use Committee (protocol number A031505). 
Experimental Design 
 Male frogs were chosen at random and split evenly into control or experimental 
groups. I injected all frogs in the dorsal lymph sac with either 10µL of physiological 
saline (control group) or 10µL of 5mg/mL AVT-Antagonist (β-Mercapto-β, βcyclopenta-
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methylenepropionyl1-, O-ET-Tyr2, (Val, Arg8)) vasopressin (Sigma V4253) in 
physiological saline (experimental group). This compound is a potent antagonist for the 
V1a and V2 AVT receptors. Once injected, I placed the frogs in 50mL centrifuge tubes 
along with a small amount of ice to induce inoculation and a soft-foam plug was inserted 
to immobilize specimen. Tubes were then placed into an ice bath and held for 30mins 
prior to freezing.    
 Freezing Protocol 
I placed the 50ml centrifuge tubes with the ice-inoculated frogs into a computer-
controlled ethanol bath (Thermo RTE-740) pre-cooled to 0.5ºC. I used a real-time 
temperature data logger (Omega DAQPRO5300) probe placed into one control frog tube 
to monitor temperature around the frog. Temperature was then cooled to -0.8°C, after 
which a controlled cooling rate of -0.04°C·h-1 was maintained until a temperature of -
2.5°C was reached. The frogs were held at this temperature for four hours, then removed 
from the bath and immediately dissected to remove liver and femoral muscles. Liver and 
thigh musculature were weighed and subsamples were removed and weighed to 
determine water content. The tissues and the carcass were then stored at -80°C until 
needed for physiological analyses.  
 
AVT Immunoassay Extraction Preparation 
 Frozen and unfrozen frogs were removed from storage at -80ºC were used for the 
AVT Immunoassay. I removed and weighed any large visible ice crystals from abdomen 
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of each frog. Decapitation of each frog at the base of the occipital condyles was 
performed to ensure only systemic AVT levels were measured and no pituitary stores 
would be calculated into my results. The remaining carcasses were frozen using liquid 
nitrogen and ground to a fine uniform powder with a mortar and pestle. Tissues were 
prepared using an enzymatic extraction kit (Peninsula Labs product #S-5000) on ~750mg 
of carcass powder, initially homogenized in 3mL Buffer A solution (1% trifluoroacetic 
acid). I then spun down the homogenate at 13.5k, 2ºC for 30minutes and collected the 
supernatant and froze overnight. Once the supernatant was thawed, it was centrifuged at 
13.5k for 10 minutes. I extracted 800ml of the new supernatant and ran it through SEP-
column filters and washed per instructions. The eluent from each filter was freeze dried 
for 48hours, then reconstituted with 500µL EIA buffer. This solution was used to 
determine circulating AVT levels in the Immunoassay. 
 
AVT Immunoassay Protocol 
 Immunoassay was performed using instructions provided by Peninsula Lab’s 
AVT-EIA Kit (Product # S-1239.0001). I added 50µL of either EIA buffer solution, 
standard, or sample to each well of a pretreated 96-well plate, followed by25µL of 
antiserum and a one hour incubation at room temperature. 25µL of rehydrated Bt-tracer 
in EIA buffer was added to each well and given an additional two-hour incubation. The 
plate was carefully washed and dried with 300µL of EIA buffer five times before 
receiving 100µL of streptavidin-HRP in each well, followed by a 60-minute incubation. 
The wash washed five times, 100µL of TMB-solution added and allowed incubate for an 
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additional 45 minutes. Samples were read at 540µm wavelength (Turner SP-870 
spectrophotometer), then again at one hour at 450µm wavelength after the addition of 
100µL 2N hydrochloric acid. 
 
Metabolite Assay Preparation 
 I homogenized liver and thigh musculature in ice-cold 0.6 mol·L-1 perchloric acid 
in 2mL micro-centrifuge tubes, then spun at 13.5k for 5 minutes before being neutralized 
with 1mol·L-1 potassium bicarbonate. I extracted the supernatant from each tube and 
placed it in a new, labelled -80°C-safe micro-centrifuge tube. As sample of the raw 
homogenate was placed in a labeled, -80ºC-safe micro-centrifuge tube for measurement 
of glycogen content. All other samples were placed in a -80ºC cold storage until needed 
for assays. 
 
Free glucose Assay 
I measured glucose using an assay kit (Sigma-Aldrich, product no. GAGO-20). 
Assays involved adding 50uL of the tissue extract to 1mL PGO-solution in a 2.0mL 
cuvette and allowing it to react for 45mins in darkness. I read absorbance at 450µm 
(Turner SP-870 spectrophotometer) and calculated glucose concentration was calculated 
based on comparison to a standard of known concentration (400mg/L).  
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Glycogen Assay 
 Glycogen assays were performed on100µL aliquotes of raw homogenate 
neutralized with 50µL of 1mol·L-1 potassium bicarbonate.  I then added 500µL of a 1:39 
aspergillus-enzymatic digest solution (Sigma Aldrich, CAS 9032-08-0) to the tubes and 
incubated for 2 hours at 40ºC. After which I added 250µL of 0.6N perchloric acid 
followed by 375µL 1mol·L-1 potassium bicarbonate. Tubes were centrifuged at 13.5k rpm 
for 10 minutes and analyzed using the Sigma-Aldrich free-glucose assay kit GAGO-20 as 
described above. Glucose levels obtained from this assay, minus the results of the free-
glucose test gave us the total new glycogen concentration. I tested the efficiency of the 
glycogen digest by using 55mg of bovine glycogen to 2.5mL of 0.6N perchloric acid and 
assaying the glycogen concentration using the same procedures as used for glycogen 
assay for tissues described above, I saw a ~99% efficiency rate.  
 
Glycerol Assay 
 Glycerol was measured using the free-glycerol reagent kit from Sigma-Aldrich 
(catalog no. F6428). I added 50µL of ultra-purified water, glycerol standard, or extracted 
supernatant to 800µl of free-glycerol reagent in appropriately labeled 2mL centrifuge 
tubes. Samples were then incubated for 15mins at ambient temperature. Iread the samples 
at 540nm and compared it to standards of known concentration (200mg/L). 
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Statistical Analysis 
All data were log-transformed for statistical analysis to pass normality and equal-
variance testing. Welch’s 2 sample t-tests were performed to look at differences between 
control and experimental groups, whereas analysis of covariance (ANCOVA) with 
bodyweight as the covariate was run to account for differences in body size amongst 
samples. All tests were performed in MiniTab 17.  
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CHAPTER III 
RESULTS 
Mean bodyweights (Fig 2.1) were not significantly different between control and 
experimental frogs (t = 0.07, df=14, p= 0.949). Control frogs showed a mean bodyweight 
of 3.69 ± 0.37g (n=8) while my AVT-antagonist treatment group averaged 3.65 ± 0.42g 
(mean ± SEM, n=9). This being the case, differences seen in cryoprotectant were not 
influenced by bodysize.  
 
Cryoprotectant Results 
While investigating glucose production, the AVT-antagonist group produced 
~50% of the glucose in liver samples compared to control frogs (Fig 2.2). Control frogs 
showed a mean glucose level of 703±66µMol/g dry mass (n=8) while my AVT-
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Figure 2.1 Mean bodyweight from control and AVT-antagonist treatment P. regilla.  
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antagonist frogs showed a concentration of 364±68µMol/g dry mass (n=9). This 
difference of mean hepatic glucose levels between control and the antagonist treated 
group was statistically significant (t= 3.58, df=14, p= 0.003).   
  
This trend did not hold true, however, within thigh samples (Fig 2.3). Free glucose 
levels within the AVT-antagonist treated group were not significantly different from the 
control in the thigh samples (t= -0.36, df=10, p= 0.728). Control frogs averaged 
26±6µMol/g dry mass (n=8). Amongst my AVT-antagonist treated group, mean thigh 
glucose levels measured 28±3µMol/g dry mass (n=9).  
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Figure 2.2 Mean hepatic glucose from control and AVT-antagonist treatment P. 
regilla.  
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Hepatic glycerol levels of the AVT-antagonist frogs showed a 40% reduction 
compared to control frogs (Fig 2.4). Control frogs showed a mean hepatic glycerol level 
of 5.1±0.8µMol/g dry mass (n=8), AVT-antagonist group 3.2±0.7µMol/g dry mass (n=9). 
Liver glycerol production was significantly influenced by body size as well (f= 12.06, 
df=1, p=0.004). Thigh glycerol levels (Fig 2.5) showed no significant difference between 
control and AVT-antagonist groups (t=1.21, df=1, p=0.247). Control value for thigh 
glycerol were 3.2±0.6µMol/g dry mass (n=8). AVT-antagonist values 2.2±0.5µMol/g dry 
mass (n=9).  Bodyweight contributed significantly to glycerol levels as well, with larger 
Figure 2.3 Mean thigh glucose from control and AVT-antagonist treatment P. regilla.  
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frogs producing larger amounts of glycerol (f= 7.15, df=1, p = 0.019).   
 
I found mean hepatic glycogen levels within control frogs of 644.6±234.2µMol/g 
dry mass (n=8) (Fig. 2.6). In my AVT-antagonist group, values produced a mean of 
676.6±171.1µMol/g dry mass (n=9). These results produced no significant difference. 
Knowing that muscular glycogen is utilized primarily for localized energy demands as it 
lacks the G6Pase enzyme (Gerin and Van Shaftingen, 2002), I felt it was unnecessary to 
measure glycogen content within thigh samples. 
 
 
 
 
Figure 2.4 Mean hepatic glycerol concentrations from control and AVT-antagonist 
treatment P.regilla.  
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AVT Immunoassay results 
 I observed that frozen frogs had over double the measurable AVT levels over 
unfrozen control frogs (0.42±0.1 ng/g vs. 1.04 ±0.65ng/g; t=0.05, p=0.05) (Fig. 2.7).  
 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
6
T
h
ig
h
 G
ly
ce
ro
l (
µ
M
o
l/
g)
Control                                       Experimental
Figure 2.5 Mean thigh glycerol concentrations from control and AVT-antagonist 
treatment P.regilla.  
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Figure 2.6 Mean hepatic glycogen from control and AVT-antagonist treatment P. 
regilla  
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Figure 2.7 Mean AVT concentration from unfrozen control and frozen P. regilla  
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CHAPTER IV 
DISCUSSION 
Freezing and Cryoprotectant Accumulation in Pseudacris regilla 
Freeze-tolerant amphibians use glucose and glycerol as cryoprotectants to combat 
the stressors associated with freezing (i.e., ice formation, dehydration: Storey and Storey 
1996; Irwin and Lee, 2003; Costanzo et al., 2013). Freezing drives up hepatic glucose 
levels nearly 20-fold in Hyla versicolor and Hyla chrysoscelis (Irwin and Lee, 2003). In 
Rana sylvatica hepatic glucose levels went from ~3µMol/g wet wt. to 236µMol/g wet wt. 
with freezing (Storey and Storey, 1996). Similarly, a Northern California population of P. 
regilla exhibited a 5 to11-fold increase in liver glucose levels during freezing, with levels 
reaching ~100µMol/g wet wt. (Croes and Thomas, 2000).  I saw even higher hepatic 
glucose levels, reaching ~266µMol/g wet wt. (Fig. 2.2). My results are comparable to 
cryoprotectant accumulation with several other known species of freeze-tolerant 
amphibians, suggested that the glucose produced in cryoprotective as it is in other 
amphibian species.  
  Because glycogen is the dominate source of glucose, I measured the glycogen 
content within P.regilla and compared it to previous works. I saw similar patterns as in 
previous investigations, with my population showing a mean glycogen level of around 
245µMol/g wet wt. (Fig. 2.6) and Californian P. regilla producing 362µMol/g wet wt. 
(Croes and Thomas, 2000). Seasonal and geographical variations in glycogen stores have 
been well documented within amphibians, including those known to be freeze-tolerant 
and other members of the genus Pseudacris (Pinder et al., 1992; Dismore and Swanson, 
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2008; Costanzo et. al., 2013). Knowing that variation is likely to be seen with different 
populations of P. regilla, seeing a marginal variation like I did between my finding vs. 
Croes and Thomas would be likely and would not suggest any less capacity for freeze 
tolerance.  
Croes and Thomas’s study also noted a 2 to 3-fold increase in glycerol, another 
cryoprotectant used by freeze-tolerant amphibians (Zimmerman et al., 2007). My results 
showed glycerol accumulations around one third of that seen in the work of Croes and 
Thomas with P. regilla reaching only 1.92µMol/g wet wt (5.10µMol/g dry wt) (Fig. 2.4). 
Again, seasonal and geographical variation may very well explain the difference 
measured by Croes and Thomas vs. my findings within P. regilla.  
 
Arginine Vasotocin, Freezing and Cryoprotectants  
 The concentration of circulating AVT levels has never been studied in freeze-
tolerant amphibians. In this current study, I measured a significant increase in systemic 
AVT levels within frozen Pseudacris regilla. Frozen frogs had more than double the 
systemic AVT levels of control frogs (0.42ng/g vs. 1.04ng/g) (Fig. 2.7). This supports my 
hypothesis that AVT is involved during freezing, and is the first experiment to show an 
elevation of AVT during freezing in any freeze-tolerant amphibian.  
Although never directly measured before, there was much reason to predict that 
freezing would increase AVT concentrations. Studies have shown internal organs lose up 
to 60% of their water content during freezing (Lee et al., 2002) which would activate 
physiological responses to dehydration like the release of AVT.  For example, frogs and 
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axolotls elevate in systemic AVT when faced with osmotic stress events like dehydration 
(Maejima et al., 2008; Uchiyama et al., 2014). AVT affects water movement by acting on 
the permeability of tissues throughout the body, including the integumentary and urinary 
systems (Tanii et al., 2002; Hasegawa et al., 2003; Suzuki et al., 2006; Ogushi et al., 
2010). Several families of aquaporins are directly mediated by AVT as well (Suzuki et al., 
2006). Aquaporins affect the movement of not only water, but small solutes such as 
glycerol and urea. It has already been seen in several freeze-tolerant species that glycerol 
elevations occur during freezing (Croes and Thomas, 2000; Zimmerman et al., 2007). It 
has also been observed that elevations of AVT-mediated aquaporins do occur during 
freezing (Zimmerman et al., 2007). Freezing would induce both osmoregulatory 
challenges the need for cryoprotectants, both of which could be provided by AVT. Indeed, 
my results confirm this hypothesis: AVT increases during freezing and is likely being 
used to stimulate cryoprotectant production and movement, along with its involvement in 
osmoregulation. 
My study is the first to observe a direct relationship between AVT and 
cryoprotectant accumulation during freezing. Under influence of the AVT antagonist, I 
saw a dramatic decrease in hepatic glucose concentrations (702.6 vs. 363.8 µMol/g dry 
wt).. This is consistent with other studies demonstrating the glycogenolytic effects of 
AVT in amphibians (Janssens et al., 1985; Ade et. al., 1995). This effect is linked to AVT 
increasing the activity of glycogen phosphorylase (GP), the initiating enzyme of 
glycogenolysis (Ade et al., 1995; Boyd, 2006). 
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AVT also plays a role in glycerol production. The AVT antagonist reduced 
glycerol accumulation within the liver by~40% from 5.1 to 3.1 µMol/g dry wt. Glycerol 
can be obtained through two mechanisms, glycolysis or lipolysis. There is no research to 
date that has measured the extent to which each pathway is involved with regards to total 
glycerol output during freezing in amphibians. This study, as well as others, have already 
shown glucose production is affected by AVT during freezing within P. regilla. Glycerol 
production may also be bound by same relationship, as glucose and glucose 6-phosphate 
are precursors in the glycolytic production of glycerol. 
Glycerol movement may also be influenced by AVT. Glycerol must be allowed to 
travel through cells to necessary areas to play its cryoprotective role, and the movement 
of glycerol is in large part facilitated by AQPs/GLPs under regulatory control by AVT 
(Boyd, 2006; Suzuki et al., 2006; Krane and Goldstein, 2007; Ogushi et al., 2010). 
Without upregulation of these necessary transportation mechanisms, it is likely the 
movement of glycerol could also be directly influenced by AVT. It is also possible this 
could be a factor in the reduction of total hepatic glycerol levels seen in my AVT 
antagonist-treatment frogs. With AVT inhibited, both production and movement of 
glycerol can be effected and again I measured a significant reduction in hepatic glycerol 
under these conditions. 
 I hypothesized that liver glycogen levels would be higher after exposure to the 
AVT antagonist, as these frogs would use less glycogen to produce the lower levels of 
cryoprotectants observed. Mean glycogen levels for control frozen frogs came in at 
644.6±234.2µMol/g dry mass, while AVT-antagonist treated frogs produced 
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676.6±171.1µMol/g dry mass. The lack of statistical difference in glycogen levels seen in 
my results is likely due to the natural variation seen amongst individuals. It is clear AVT 
does play a role in cryoprotectant accumulation during freezing in P. regilla and further 
investigation into understating the biochemical/physiological processes involved 
certainly are merited. 
   
AVT, Epinephrine & cAMP signaling 
Epinephrine (β-adrenergic) activity has also been documented in influencing the 
levels of cryoprotectant accumulation in various freeze-tolerant species (Ade et al., 1995; 
Storey and Storey, 1996; Amaral et al., 2015). Similar studies have also shown that with 
the use of propranolol, a β-adrenergic antagonist, frogs saw a significantly reduced 
accumulation of hepatic glucose during freezing (236µMol/g wet wt. vs 130µMol/g wet 
wt.)(Storey and Storey, 1996). This reduction is in hepatic glucose is very similar to that 
observed within my AVT-antagonist group. The rise in glycogenolysis through increased 
AVT-mediated, GP activity has been shown to be linked directly to an increase in cAMP 
concentration within the tissues (Ade et al., 1995; Janssens et al., 1985). Indeed, in both 
AVT and β-adrenergic activation of glycogenolysis, the cAMP intracellular pathway 
mediates glycogenolysis (Janssens and Grigg, 1992). Similarly, I speculate that AVT is 
acting along with epinephrine to influence cAMP concentrations within tissues, which 
increases activity of GP to produce more glucose during freezing events. AVT may also 
be enhancing beneficial water movements as several families of AQPs and GLPs in 
freeze-tolerant tree frogs have also been shown to be regulated by both AVT and 
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epinephrine, including the HC-3 GLP (Zimmerman et al., 2007; Ogushi et al., 2009; 
Ratycz, 2014).  
 My results indicate that AVT and epinephrine have overlapping effects on 
cryoprotectant production. Since both of these glycogenolytic responses are mediated by 
cAMP, future work to measure cAMP fluctuations -especially after administration of the 
AVT antagonist and/or propranolol - during freezing may help us understand the extent 
AVT and epinephrine have on responses to freezing. Can glucose production be 
suppressed to control levels when exposed to both AVT-antagonist and propranolol? How 
is glycerol production and movement affected when exposed to various combinations of 
AVT and epinephrine in tandem?  Future work using both AVT and β-adrenergic 
agonists/antagonists in various combinations might provide powerful insight into the 
intermingled relationship of AVT and epinephrine affect amphibian freeze tolerance. 
Overall, this is the first study to both confirm elevations in systemic AVT during 
freezing in P. regilla and that cryoprotectant outputs are suppressed when AVT is 
inhibited during freezing. Both provide useful evidence and offer more insight into 
understanding the biochemical processes involved in freeze-tolerance.  
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